Latest Insider Transactions at Biomea Fusion, Inc. (BMEA)
This section provides a real-time view of insider transactions for Biomea Fusion, Inc. (BMEA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Biomea Fusion, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Biomea Fusion, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2024
|
Michael J.M. Hitchcock |
BUY
Open market or private purchase
|
Direct |
10,000
+40.0%
|
$100,000
$10.06 P/Share
|
|
Jun 11
2024
|
Franco Valle Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
12,509
+22.74%
|
$50,036
$4.43 P/Share
|
|
May 31
2024
|
Juan Pablo Frias Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
349
+50.0%
|
$2,792
$8.94 P/Share
|
|
May 31
2024
|
Franco Valle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,448
+12.92%
|
$13,344
$3.78 P/Share
|
|
Dec 29
2023
|
Rainer M Erdtmann President and COO |
SELL
Bona fide gift
|
Direct |
21,000
-0.72%
|
-
|
|
Dec 29
2023
|
Rainer M Erdtmann President and COO |
BUY
Bona fide gift
|
Indirect |
9,000
+23.45%
|
-
|
|
Nov 30
2023
|
Franco Valle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,345
+5.0%
|
$4,035
$3.78 P/Share
|
|
Jun 01
2023
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
50,000
-1.41%
|
$1,700,000
$34.56 P/Share
|
|
May 31
2023
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
75,000
-2.07%
|
$2,475,000
$33.81 P/Share
|
|
May 31
2023
|
Franco Valle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,273
+15.01%
|
$12,819
$3.78 P/Share
|
|
May 12
2023
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
25,000
-0.68%
|
$825,000
$33.84 P/Share
|
|
May 09
2023
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
150,000
-3.95%
|
$5,100,000
$34.5 P/Share
|
|
May 08
2023
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
100,000
-2.56%
|
$3,300,000
$33.99 P/Share
|
|
Apr 20
2023
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
200,000
-4.88%
|
$5,800,000
$29.12 P/Share
|
|
Mar 31
2023
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
BUY
Open market or private sale
|
Direct |
200,000
+4.65%
|
$6,200,000
$31.25 P/Share
|
|
Mar 30
2023
|
Bihua Chen |
BUY
Open market or private purchase
|
Indirect |
400,000
+10.07%
|
$12,000,000
$30.0 P/Share
|
|
Nov 30
2022
|
Franco Valle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+11.22%
|
$7,554
$3.78 P/Share
|
|
Nov 14
2022
|
Michael J.M. Hitchcock |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$35,000
$7.93 P/Share
|
|
Nov 11
2022
|
Franco Valle Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
4,100
+19.06%
|
$28,700
$7.63 P/Share
|
|
Aug 16
2022
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private purchase
|
Direct |
30,684
-0.71%
|
$398,892
$13.87 P/Share
|
|
Jul 21
2022
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
34,658
-0.79%
|
$381,238
$11.21 P/Share
|
|
Jun 24
2022
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
34,658
-0.79%
|
$381,238
$11.76 P/Share
|
|
Jun 01
2022
|
Biomea Health, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
4,365,342
-100.0%
|
-
|
|
May 31
2022
|
Franco Valle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,307
+19.9%
|
$13,228
$4.67 P/Share
|
|
Jan 14
2022
|
Franco Valle Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$80,000
$8.68 P/Share
|
|
Sep 17
2021
|
Sotirios Stergiopoulos Director |
BUY
Open market or private purchase
|
Indirect |
34,658
+0.78%
|
$346,580
$10.96 P/Share
|
|
Sep 17
2021
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
34,658
+0.78%
|
$346,580
$10.96 P/Share
|
|
Aug 23
2021
|
Thomas Andrew Butler Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
24,000
+9.51%
|
$312,000
$13.2 P/Share
|
|
Aug 23
2021
|
Rainer M Erdtmann President and COO |
BUY
Open market or private purchase
|
Indirect |
24,000
+9.51%
|
$312,000
$13.2 P/Share
|
|
Aug 18
2021
|
Thomas Andrew Butler Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
14,000
+6.41%
|
$140,000
$10.77 P/Share
|
|
Aug 18
2021
|
Rainer M Erdtmann President and COO |
BUY
Open market or private purchase
|
Indirect |
14,000
+6.41%
|
$140,000
$10.77 P/Share
|
|
Aug 17
2021
|
Thomas Andrew Butler Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
14,000
+6.85%
|
$140,000
$10.79 P/Share
|
|
Aug 17
2021
|
Rainer M Erdtmann President and COO |
BUY
Open market or private purchase
|
Indirect |
14,000
+6.85%
|
$140,000
$10.79 P/Share
|
|
Apr 20
2021
|
Bihua Chen |
BUY
Open market or private purchase
|
Indirect |
900,000
+22.11%
|
$15,300,000
$17.0 P/Share
|
|
Apr 20
2021
|
Bihua Chen |
BUY
Conversion of derivative security
|
Indirect |
2,270,872
+50.0%
|
-
|
|
Apr 15
2021
|
Thomas Andrew Butler Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
176,470
+50.0%
|
$2,999,990
$17.0 P/Share
|
|
Apr 15
2021
|
Rainer M Erdtmann President and COO |
BUY
Open market or private purchase
|
Indirect |
176,470
+50.0%
|
$2,999,990
$17.0 P/Share
|